GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cadence Pharmaceuticals, Inc. (FRA:QEW) » Definitions » Operating Margin %

Cadence Pharmaceuticals, (FRA:QEW) Operating Margin % : -8.49% (As of Dec. 2013)


View and export this data going back to . Start your Free Trial

What is Cadence Pharmaceuticals, Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Cadence Pharmaceuticals,'s Operating Income for the three months ended in Dec. 2013 was €-2.19 Mil. Cadence Pharmaceuticals,'s Revenue for the three months ended in Dec. 2013 was €25.78 Mil. Therefore, Cadence Pharmaceuticals,'s Operating Margin % for the quarter that ended in Dec. 2013 was -8.49%.

The historical rank and industry rank for Cadence Pharmaceuticals,'s Operating Margin % or its related term are showing as below:


FRA:QEW's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -156.305
* Ranked among companies with meaningful Operating Margin % only.

Cadence Pharmaceuticals,'s 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cadence Pharmaceuticals,'s Operating Income for the three months ended in Dec. 2013 was €-2.19 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2013 was €-20.85 Mil.


Cadence Pharmaceuticals, Operating Margin % Historical Data

The historical data trend for Cadence Pharmaceuticals,'s Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cadence Pharmaceuticals, Operating Margin % Chart

Cadence Pharmaceuticals, Annual Data
Trend Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -531.52 -152.79 -24.47

Cadence Pharmaceuticals, Quarterly Data
Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -118.35 -33.62 -43.73 -20.10 -8.49

Competitive Comparison of Cadence Pharmaceuticals,'s Operating Margin %

For the Biotechnology subindustry, Cadence Pharmaceuticals,'s Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cadence Pharmaceuticals,'s Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cadence Pharmaceuticals,'s Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cadence Pharmaceuticals,'s Operating Margin % falls into.



Cadence Pharmaceuticals, Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cadence Pharmaceuticals,'s Operating Margin % for the fiscal year that ended in Dec. 2013 is calculated as

Operating Margin %=Operating Income (A: Dec. 2013 ) / Revenue (A: Dec. 2013 )
=-20.107 / 82.166
=-24.47 %

Cadence Pharmaceuticals,'s Operating Margin % for the quarter that ended in Dec. 2013 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2013 ) / Revenue (Q: Dec. 2013 )
=-2.188 / 25.778
=-8.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cadence Pharmaceuticals,  (FRA:QEW) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cadence Pharmaceuticals, Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cadence Pharmaceuticals,'s Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cadence Pharmaceuticals, (FRA:QEW) Business Description

Traded in Other Exchanges
N/A
Address
Cadence Pharmaceuticals, Inc. is a biopharmaceutical company focused on in-licensing, developing and commercializing product candidates mainly for use in the hospital setting. The Company's main activities are conducting research and development activities as well as conducting clinical trials. The company has in-licensed rights to products: Acetavance, an intravenous formulation of acetaminophen, and Omigard, an omiganan pentahydrochloride 1% aqueous gel. It in-licensed the exclusive United States, or U.S., and Canadian rights to Acetavance from Bristol-Myers Squibb Company, or BMS, which markets this product candidate in Europe and other markets for the treatment of acute pain and fever under the brand name Perfalgan. The Company is developing Acetavance, a proprietary intravenous formulation of acetaminophen, for the U.S. market for the treatment of acute pain and fever in adults and children. In its oral form, acetaminophen is the most widely used drug for the treatment of pain and fever in the U.S. The Company's licensor, BMS, currently markets this proprietary intravenous formulation of acetaminophen for the treatment of acute pain and fever in Europe and several other markets outside the U.S, where it is known as paracetamol and is marketed under the brand name Perfalgan.

Cadence Pharmaceuticals, (FRA:QEW) Headlines

No Headlines